Pregnancy and virologic response to antiretroviral therapy in South Africa. 2011

Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
Department of Obstetrics and Gynecology, Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America. daniel.westreich@duke.edu

BACKGROUND Although women of reproductive age are the largest group of HIV-infected individuals in sub-Saharan Africa, little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in that setting. We examined the effect of incident pregnancy after HAART initiation on virologic response to HAART. RESULTS We evaluated a prospective clinical cohort of adult women who initiated HAART in Johannesburg, South Africa between 1 April 2004 and 30 September 2009, and followed up until an event, death, transfer, drop-out, or administrative end of follow-up on 31 March 2010. Women over age 45 and women who were pregnant at HAART initiation were excluded from the study; final sample size for analysis was 5,494 women. Main exposure was incident pregnancy, experienced by 541 women; main outcome was virologic failure, defined as a failure to suppress virus to ≤ 400 copies/ml by six months or virologic rebound >400 copies/ml thereafter. We calculated adjusted hazard ratios using marginal structural Cox proportional hazards models and weighted lifetable analysis to calculate adjusted five-year risk differences. The weighted hazard ratio for the effect of pregnancy on time to virologic failure was 1.34 (95% confidence limit [CL] 1.02, 1.78). Sensitivity analyses generally confirmed these main results. CONCLUSIONS Incident pregnancy after HAART initiation was associated with modest increases in both relative and absolute risks of virologic failure, although uncontrolled confounding cannot be ruled out. Nonetheless, these results reinforce that family planning is an essential part of care for HIV-positive women in sub-Saharan Africa. More work is needed to confirm these findings and to explore specific etiologic pathways by which such effects may operate.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
August 2012, Journal of acquired immune deficiency syndromes (1999),
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
August 2010, Journal of acquired immune deficiency syndromes (1999),
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
January 2012, PloS one,
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
March 2011, Journal of acquired immune deficiency syndromes (1999),
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
June 2004, Current HIV/AIDS reports,
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
February 2002, Current infectious disease reports,
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
February 2015, The Pediatric infectious disease journal,
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
August 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
April 2010, Journal of acquired immune deficiency syndromes (1999),
Daniel Westreich, and Stephen R Cole, and Shashi Nagar, and Mhairi Maskew, and Charles van der Horst, and Ian Sanne
December 1998, AIDS (London, England),
Copied contents to your clipboard!